An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma

Abstract

BackgroundLung adenocarcinoma is a heterogernous disease that creates challenges for classification and management. The purpose of this study is to identify specific miRNA markers closely associated with the survival of LUAD patients from a large dataset of significantly altered miRNAs, and to assess the prognostic value of this miRNA expression profile for OS in patients with LUAD.MethodsWe obtained miRNA expression profiles and corresponding clinical information for 372 LUAD patients from The Cancer Genome Atlas (TCGA), and identified the most significantly altered miRNAs between tumor and normal samples. Using survival analysis and supervised principal components method, we identified an eight-miRNA signature for the prediction of overall survival (OS) of LUAD patients. The relationship between OS and the identified miRNA signature was self-validated in the TCGA cohort (randomly classified into two subgroups: n = 186 for the training set and n = 186 for the testing set). Survival receiver operating characteristic (ROC) analysis was used to assess the performance of survival prediction. The biological relevance of putative miRNA targets was also analyzed using bioinformatics.ResultsSixteen of the 111 most significantly altered miRNAs were associated with OS across different clinical subclasses of the TCGA-derived LUAD cohort. A linear prognostic model of eight miRNAs (miR-31, miR-196b, miR-766, miR-519a-1, miR-375, miR-187, miR-331 and miR-101-1) was constructed and weighted by the importance scores from the supervised principal component method to divide patients into high- and low-risk groups. Patients assigned to the high-risk group exhibited poor OS compared with patients in the low-risk group (hazard ratio [HR] = 1.99, P <0.001). The eight-miRNA signature is an independent prognostic marker of OS of LUAD patients and demonstrates good performance for predicting 5-year OS (Area Under the respective ROC Curves [AUC] = 0.626, P = 0.003), especially for non-smokers (AUC = 0.686, P = 0.023).ConclusionsWe identified an eight-miRNA signature that is prognostic of LUAD. The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.

Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma

“…27 Many studies have demonstrated that miRNAs are released into the circulation and exist in markedly stable form. 13,14 The first serum miRNA biomarker discovered was miR-21, which was found in high serum levels associated with increased relapse-free survival in patients with diffuse large B-cell lymphoma.…”

Plasma miR-187* is a potential biomarker for oral carcinoma

“…Although the upregulation of miR-187 expression has been observed and the oncogenic role of this marker has been identified in many neoplasms [1,25,26], the expression and function of miR-187*, the passenger strand derived from same precursor hairpin, has remained unexplored in OSCC. This study provides novel evidence that miR-187*, which is co-expressed with miR-187, is also a distinct and functional miRNA.…”

“…Aberrant expression of miR-187 (miR-187-3p) has been identified in various cancers including renal [17], pancreatic [18], thyroid [19], gastric [20], esophageal [21], prostate [22], breast [23,24], ovarian [25], and lung carcinomas [26]; however, as miR-187 expression varies greatly across different tumors, the mechanism of its involvement in carcinogenesis could be tissue specific. Blenkiron et al [23] have observed miR-187 overexpression in estrogen receptor negative (ERnegative) as compared with ER-positive tumors, and miR-187 seems to be over-represented in HER2-positive cancers, whereas Mulrane et al [24] have noted that the expression of the miR-187 is increased more than 2.6-fold in breast cancer as compared with normal tissue.…”

A practical prognostic lncRNA signature for lung squamous cell carcinoma

“…For subsequent model development, we randomly divided all the patients into the training set (n = 194) and testing set (n = 194) as previously reported [21,22]. There was no significant difference in the clinical covariates between the two sets (P > 0.05) ( Table 1).…”